©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatr. Aug 19, 2020; 10(8): 175-186
Published online Aug 19, 2020. doi: 10.5498/wjp.v10.i8.175
Published online Aug 19, 2020. doi: 10.5498/wjp.v10.i8.175
Serum levels of chemokines in adolescents with major depression treated with fluoxetine
Francisco Rafael de la Peña, Lino Palacios, Adolescent Clinic, Clinical Services, National Institute of Psychiatry, “Ramón de la Fuente”, Mexico City 14370, Mexico
Carlos Cruz-Fuentes, Department of Psychiatric Genetics, Clinical Research Branch, National Institute of Psychiatry, “Ramón de la Fuente”, Mexico City 14370, Mexico
Manuel Iván Girón-Pérez, Universidad Autónoma de Nayarit, Laboratorio de Inmunotoxicología, Boulevard Tepic-Xalisco s/n, Cd de la Cultura Amado Nervo, Tepic 63000, Mexico
Manuel Iván Girón-Pérez, Centro Nayarita de Innovación y Transferencia de Tecnología A.C. Laboratorio Nacional para la Investigación en Inocuidad Alimentaria-Unidad Nayarit, Calle Tres s/n. Cd Industrial, Tepic 63000, Nayarit, Mexico
Emilio Medina-Rivero, Unidad de Desarrollo e Investigación en Bioprocesos, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Unidad Profesional Lázaro Cárdenas, Mexico City 11340, Mexico
Maria Dolores Ponce-Regalado, Departamento de Ciencias de Salud, Centro Universitario de los Altos, Universidad de Guadalajara Av Rafael Casillas Aceves No.1200, Tepatitlán de Morelos, Jalisco, 47610, Mexico
Samantha Alvarez-Herrera, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, José Luis Maldonado-García, Lenin Pavón, Laboratory of Psychoimmunology, National Institute of Psychiatry, “Ramón de la Fuente”, Mexico City 14370, Mexico
María C Jiménez-Martínez, Department of Immunology and Research Unit, Institute of Ophthalmology “Conde de Valenciana Foundation”, Mexico City 06800, Mexico
María C Jiménez-Martínez, Department of Biochemistry, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico
Author contributions: de la Peña FR, Cruz-Fuentes C, and Pavón L designed the study and wrote the protocol; de la Peña FR, Palacios L, Ponce-Regalado MD, Maldonado-García JL, Jiménez-Martínez MC, and Pavón L supervised the patients’ recruitment; Girón-Pérez MI, Medina-Rivero E, Ponce-Regalado MD, Alvarez-Herrera S, Pérez-Sánchez G, and Becerril-Villanueva E collected the biological samples and conducted the experimental determinations; Pavón L supervised the development of all experiments; Palacios L, Girón-Pérez MI, Medina-Rivero E, Ponce-Regalado MD, Alvarez-Herrera S, Pérez-Sánchez G, Becerril-Villanueva E, Maldonado-García JL, Jiménez-Martínez MC, and Pavón L analyzed the results; All authors approved the final manuscript.
Supported by Secretaria de Ciencia, Tecnología e Innovación , No. 0048/2014
Institutional review board statement: The study was reviewed and approved by the ethics committee of the Instituto Nacional de Psiquiatria “Ramón de la Fuente Muñiz” (México).
Conflict-of-interest statement: The authors report no conflicts of interest in relation to the topic of this study.
Data sharing statement: Data of the studies are not publicly available but might be shared upon request from the corresponding author.
Corresponding author: Lenin Pavón, PhD, Professor, Laboratory of Psychoimmunology, National Institute of Psychiatry, “Ramón de la Fuente”, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Mexico City 14370, Mexico. lkuriaki@imp.edu.mx
Received: February 29, 2020
Peer-review started: February 29, 2020
First decision: April 29, 2020
Revised: May 31, 2020
Accepted: June 27, 2020
Article in press: June 27, 2020
Published online: August 19, 2020
Processing time: 166 Days and 0.1 Hours
Peer-review started: February 29, 2020
First decision: April 29, 2020
Revised: May 31, 2020
Accepted: June 27, 2020
Article in press: June 27, 2020
Published online: August 19, 2020
Processing time: 166 Days and 0.1 Hours
Core Tip
Core tip: Major depressive disorder affects 350 million persons, of whom approximately 6% are adolescents. This study determined the differences in circulatory levels of chemokines including eotaxin, interleukin-8, induced protein 10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, and macrophage inflammatory protein-1β in healthy volunteers and adolescents with major depression. In addition, the changes induced by antidepressants consumed during 8 wk of clinical follow-up were assessed, which is the minimum time to observe the therapeutic efficacy of selective serotonin reuptake inhibitors, such as fluoxetine in adolescents. Our results showed significant elevation in serum chemokine levels in adolescents with major depression despite treatment with fluoxetine, and an improvement in scores on the Hamilton depresión rating scale.